Blue Water Life Science Advisors, LP
Long book
$124.7M
Q1 2026
Positions
10
Top-10 weight
100%
concentration
Last quarter
+73.0%
SPY +14.8%
Turnover
27%
of book per quarter
Strategy in plain words
auto-generated from filingsBlue Water Life Science Advisors, LP is a concentrated fundamental stock-picker, specialised in healthcare (94% of the long book), running a $124.7M US long book across 10 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: 10X GENOMICS INC-CLASS A, GUARDANT HEALTH INC, CAREDX INC, ADAPTIVE BIOTECHNOLOGIES, TWIST BIOSCIENCE CORP.
Over the last 9 quarters its long book ran on average 13.4pp per quarter ahead of the S&P 500, beating the index in 7 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+10.5%
Q2 2024
+16.2%
Q3 2024
+7.4%
Q4 2024
+4.0%
Q1 2025
+27.8%
Q2 2025
+4.7%
Q3 2025
+29.6%
Q4 2025
-12.3%
Q1 2026
+73.0%
Sector allocation
Healthcare 94%
Technology 6%
Long book by quarter
What does Blue Water own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| TXG 10X GENOMICS INC-CLASS A | Healthcare | 1.1M | $23.1M | 18.6% | New |
| GH GUARDANT HEALTH INC | Healthcare | 242.2K | $22.4M | 17.9% | -31.8% |
| CDNA CAREDX INC | Healthcare | 935.0K | $16.2M | 13.0% | +83.3% |
| ADPT ADAPTIVE BIOTECHNOLOGIES | Healthcare | 1.0M | $14.0M | 11.2% | -42.8% |
| TWST TWIST BIOSCIENCE CORP | Healthcare | 276.0K | $13.1M | 10.5% | -27.9% |
| PSNL PERSONALIS INC | Healthcare | 1.7M | $10.7M | 8.6% | Held |
| NTRA NATERA INC | Healthcare | 44.8K | $9.0M | 7.2% | -68.3% |
| QTRX QUANTERIX CORP | Healthcare | 2.1M | $7.5M | 6.0% | +2.4% |
| TEM TEMPUS AI INC-CL A | Technology | 156.4K | $7.1M | 5.7% | +81.0% |
| BLLN BILLIONTOONE INC CL A | Healthcare | 20.0K | $1.6M | 1.3% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 10 | $124.7M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 9 | $159.3M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 7 | $109.6M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 8 | $126.3M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 7 | $100.9M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 9 | $112.9M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 8 | $113.7M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 9, 2024 | 8 | $102.8M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 8 | $106.3M | canonical | SEC ↗ |